Richard Mulligan

Insider Reports History

Identity
Location
Seattle, WA
SEC record
Reporting signature
/s/ Chrystalla Potamitou, attorney in fact
SEC evidence
Transaction evidence
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Holdings reported by Richard Mulligan:

Form 4 holding Director

Sana Biotechnology, Inc.

Security class
Common Stock
Shares / value
2,698,121
Estimated value
$10,489,755
Report date
25 Sep 2024
Price
$3.89
Ownership
Direct
Form 4 holding Director

BIOGEN INC.

Security class
Common Stock
Shares / value
15,099
Estimated value
$3,744,552
Report date
15 Jun 2022
Price
$248.00
Ownership
Direct
Form 4 holding Director

Bausch Health Companies Inc.

Security class
Common Shares, No Par Value
Shares / value
101,269
Estimated value
$1,074,464
Report date
17 May 2024
Price
$10.61
Ownership
Direct

Insider Reports Filed by Richard Mulligan

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .